> Detailanzeige

Costedoat, Ingrid; Wallaert, Martin; Gaultier, Aurelie; Vasseur, Robin; Vanhaecke, Clelia; Viguier, Manuelle; Cordelette, Charles; Denoyer, Alexandre; Ferrier le Bouëdec, Marie‐Christine; Coutu, Adrien; Lamiaux, Marie; Tran, Thi Ha Châu; Lacour, Jean Philippe; Elmaleh, Valerie; Tetart, Florence; Gueudry, Julie; Tauber, Marie; Giordano‐Labadie, Francoise; Cassagne, Myriam; Nosbaum, Audrey; Ouilhon, Coralie; Jachiet, Marie; Tadayoni, Ramin; Dezoteux, Frederic; [...]

Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients
  • Beteiligte: Costedoat, Ingrid; Wallaert, Martin; Gaultier, Aurelie; Vasseur, Robin; Vanhaecke, Clelia; Viguier, Manuelle; Cordelette, Charles; Denoyer, Alexandre; Ferrier le Bouëdec, Marie‐Christine; Coutu, Adrien; Lamiaux, Marie; Tran, Thi Ha Châu; Lacour, Jean Philippe; Elmaleh, Valerie; Tetart, Florence; Gueudry, Julie; Tauber, Marie; Giordano‐Labadie, Francoise; Cassagne, Myriam; Nosbaum, Audrey; Ouilhon, Coralie; Jachiet, Marie; Tadayoni, Ramin; Dezoteux, Frederic; [...]
  • Erschienen: Wiley, 2023
  • Erschienen in: Journal of the European Academy of Dermatology and Venereology
  • Sprache: Englisch
  • DOI: 10.1111/jdv.18932
  • ISSN: 1468-3083; 0926-9959
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo (<jats:italic>n</jats:italic> = 32) or worsening of underlying blepharoconjunctivitis (<jats:italic>n</jats:italic> = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; <jats:italic>p</jats:italic> = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; <jats:italic>p</jats:italic> = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; <jats:italic>p</jats:italic> = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis.</jats:p></jats:sec><jats:sec><jats:title>Limitations</jats:title><jats:p>Our follow‐up period was 16 weeks and some late‐onset time effects may still occur.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.</jats:p></jats:sec>